Dr. Evan Yu presents the new evidence-based guideline on genetic testing for metastatic prostate cancer. He discusses who should receive germline and somatic testing with next-generation sequencing ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Final results of the OCEAN(a)-DOSE trial – published in the New England Journal of Medicine – showed that the small, interfering RNA (siRNA) drug reduced Lp(a) levels compared to placebo at ...

Now, an alliance between Novartis and genetic testing specialist 23andMe is trying to encourage greater awareness of Lp(a) and improve testing rates. The pilot programme will see a confidential ...

In this article, we are going to take a look at where Energy Transfer LP (NYSE:ET) stands against the other dividend stocks. Macroeconomic factors have weighed on US stocks in the final days of ...

ARMONK, N.Y., Jan. 16, 2025 /PRNewswire/ -- IBM (NYSE: IBM) today announced its intent to acquire Applications Software Technology LLC 1, a global Oracle consultancy. Applications Software Technology ...

A new year means a new Fierce Biotech Fundraising Tracker to record all the venture capital being funneled into the industry for 2024. We're bumping up our reporting criteria from last year's ...

Getty Images / Thomas Barwick A master limited partnership (MLP) is an unusual investment that combines the tax benefits of a limited partnership (LP) with the liquidity of a common stock.

The FDA accepts Verastem's NDA for the accelerated approval of avutometinib to treat recurrent KRAS mutant ovarian cancer under priority review. The stock rises 41%. Verastem (VSTM) doses the ...

aDepartment of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USA bDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA cDepartment of Surgery, ...

There is no guarantee that they will become commercially available for the use(s) under investigation. * Lp(a) ≥ 125 nmol/L at the screening visit, measured at the Central laboratory * On Standard of ...